BrainAurora Medical Technology Ltd (06681.HK)価格

Brainaurora Medical Technology Ltd. engages in research and development of medical-grade cognitive impairment digital therapeutics (DTx) products. The company is headquartered in Shaoxing, Zhejiang and currently employs 174 full-time employees. The company went IPO on 2025-01-08. The firm's main business is engaged in offering the system integral software solutions to hospitals which enables the hospitals to offer assessment and intervention to their cognitive impairment patients. The firm is also engaged in offering research projects services as well as technical and operational support services. The firm's main product is Brain Function Information Management Platform Software System, which enables clinical assessment and interventions for various types of cognitive impairment induced by vascular diseases, neurodegenerative diseases, psychological disorders and child development deficiencies, among other types of cognitive impairments. The firm mainly conducts its business in the domestic market.